Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
331. |
ECCT/14/09/02 | LIVING STUDY-PHASE III B. Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study) |
Principal Investigator(s) 1. Elizabeth Maleche Obimbo 2. Elizabeth Bukusi 3. Winstone Nyandiko 4. Bienvenu Baruani Ngoy 5. Joseph Kariuki Mbuthia 6. Allan Godfrey Otieno 7. Lucy Koech 8. Neema Mturi 9. Beatrice Mutai Site(s) in Kenya 1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county) 2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county) 3. MSF Belgium Kibera Clinic (Nairobi City county) 4. Gertrude\'s Children\'s Hospital (Nairobi City county) 5. Mbagathi District Hospital (Nairobi City county) |
View |
332. |
ECCT/17/08/04 | P1081 A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION: NICHD P1081 |
Principal Investigator(s) 1. FREDRICK KIPYEGON SAWE Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre. |
View |
333. |
ECCT/17/05/04 | Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WALTER REED KERICHO |
View |
334. |
ECCT/24/10/06 | A5409 A Phase 2, Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB) |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) |
View |
335. |
ECCT/14/06/01 | ACTG -5279 Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Dr. Kevin N/A Cain Site(s) in Kenya 1. KEMRI/WRP CRS (Kericho county) 2. Moi University Clinical Research Center CRS ()12601 (Uasin Gishu county) |
View |